Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Dermatology

Living with PF: Disease Monitoring and Quality of Life

At a Glance

Living with pemphigus foliaceus (PF) requires careful long-term monitoring to maintain clinical remission. This includes anti-Dsg1 blood tests to predict flares, strict sun protection, gentle wound care without picking crusts, and managing the side effects of immune medications.

Living with Pemphigus Foliaceus (PF) is often described as a marathon rather than a sprint. While the initial goal is to stop the immune attack, the long-term focus shifts to survivorship—maintaining clear skin while minimizing the impact of treatment on your body and your mind.

The Science of Remission

In the world of PF, doctors aim for clinical remission, which means your skin is healed and no new lesions have appeared for at least two months. Remission can be “on therapy” (controlled by low-dose medication) or “off therapy” (no medications needed) [1].

Even when your skin is clear, your immune system requires regular check-ins. The primary tool for this is the anti-Dsg1 ELISA titer blood test.

  • Predicting Relapse: Rising levels of these antibodies in your blood can often signal that a flare-up is coming, sometimes weeks or months before you see a single flake on your skin [2][3].
  • Persistent Positives: If your titers remain high even when your skin is clear, your doctor may monitor you more closely, as this is linked to a higher risk of the disease returning [4][5].

Managing the Risks of Long-Term Treatment

The medications that keep PF under control can have their own long-term effects. Staying proactive helps you catch these issues early:

  • Bone Health: Long-term use of corticosteroids (like prednisone) can lead to bone density loss or osteoporosis [6]. Your doctor may recommend calcium, vitamin D, or a baseline bone density (DXA) scan to ensure your skeleton stays strong.
  • Immune Memory: While rituximab is a breakthrough for PF, it can sometimes “erase” or dampen your immune memory for vaccines [7]. Once your B-cells return, you and your doctor may need to discuss a plan for re-vaccination or boosters for common illnesses [8].
  • Infection Vigilance: Any immunosuppressant increases your risk of infections. Reporting even “minor” symptoms like a lingering cough or a low-grade fever is an essential part of your monitoring routine [9].

Daily Living, Wound Care, and Quality of Life

PF is a “visible” disease that can be physically and emotionally debilitating [10]. Managing the day-to-day realities of flaking skin and emotional stress is critical:

  1. Handling the Crusts (Wound Care): One of the most common questions patients have is how to handle the “corn-flake” crusts. It is vital not to pick or peel them off, as this will cause further skin damage and delay healing. Instead, your doctor may recommend gentle moisturizers (like plain petroleum jelly or thick, unscented creams) to keep the crusts soft, which helps alleviate itching and burning. Always use soap-free, gentle cleansers when showering, and pat your skin dry with a soft towel rather than rubbing.
  2. Sun Protection is Non-Negotiable: Ultraviolet (UV) light is one of the few proven environmental triggers that can cause PF to flare [11]. Strict sun protection—using broad-spectrum sunscreen, wearing sun-protective clothing, and avoiding the sun during peak hours—is a core part of managing the disease [12].
  3. The Psychosocial Toll: Living with a chronic, flaking skin condition can impact your self-esteem and social life. This is especially important for younger patients, where PF can affect psychosocial development and education [13]. You don’t have to go through this alone. Connecting with patient advocacy groups, such as the International Pemphigus & Pemphigoid Foundation (IPPF), can provide essential support and reduce feelings of isolation.

Though PF is a chronic journey, modern monitoring and treatment mean that most patients can achieve a high quality of life. By staying diligent with your blood tests and protecting your skin daily, you can stay one step ahead of the disease.

Common questions in this guide

How will my doctor monitor my pemphigus foliaceus for a relapse?
Your doctor will likely use the anti-Dsg1 ELISA titer blood test. Rising levels of these specific antibodies can signal that a flare-up is coming, often weeks or months before you develop new skin lesions.
How should I care for the skin crusts caused by PF?
It is essential not to pick or peel the crusts, as this damages the skin and delays healing. You should use gentle moisturizers like plain petroleum jelly to keep the crusts soft, wash with soap-free cleansers, and carefully pat your skin dry.
Do I need to stay out of the sun if I have pemphigus foliaceus?
Yes, strict sun protection is crucial because ultraviolet (UV) light is a known trigger that can cause the disease to flare. You should use broad-spectrum sunscreen, wear protective clothing, and avoid the sun during peak hours.
How do long-term PF treatments like steroids affect my bones?
Long-term use of corticosteroids such as prednisone can lead to bone density loss or osteoporosis. Your doctor may recommend calcium, vitamin D supplements, or a baseline bone density scan to ensure your skeleton remains strong.
Will I need to be revaccinated after taking rituximab for PF?
Rituximab can sometimes dampen your immune memory for previous vaccines. Once your B-cells return after treatment, you should discuss a plan with your doctor for getting booster shots or redoing important vaccines like flu or COVID-19.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our target anti-Dsg1 titer level, and how often will we re-test it while I am in remission?
  2. 2.Since I've been on steroids, should we schedule a DXA scan to check my bone density?
  3. 3.What specific skin care products or ingredients should I avoid to prevent irritating my fragile skin?
  4. 4.When my B-cells return after rituximab, which vaccines (like flu or COVID-19) will I need to 'redo' or booster?
  5. 5.What is the threshold for a 'flare'—at what point should I call the office between scheduled visits?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Feline pemphigus foliaceus in non-specialist veterinary practice: a retrospective analysis.

    Coyner K, Tater K, Rishniw M

    The Journal of small animal practice 2018; (59(9)):553-559 doi:10.1111/jsap.12869.

    PMID: 29961990
  2. 2

    [Possible effect of interleukin-17 blockade in pemphigus foliaceus and neutrophilic diseases].

    Kohlmann J, Simon JC, Kunz M, Treudler R

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(8)):641-644 doi:10.1007/s00105-019-4414-8.

    PMID: 31076811
  3. 3

    Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus.

    Werth VP, Culton DA, Concha JSS, et al.

    The Journal of investigative dermatology 2021; (141(12)):2858-2865.e4 doi:10.1016/j.jid.2021.04.031.

    PMID: 34126109
  4. 4

    Rituximab Therapy for Treatment of Pemphigus in Southeast Asians.

    Kanokrungsee S, Anuntrangsee T, Tankunakorn J, et al.

    Drug design, development and therapy 2021; (15()):1677-1690 doi:10.2147/DDDT.S306046.

    PMID: 33911853
  5. 5

    A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.

    Saleh MA

    Journal of the American Academy of Dermatology 2018; (79(1)):97-103 doi:10.1016/j.jaad.2018.01.029.

    PMID: 29408700
  6. 6

    Risk of Osteoporosis Associated with Glucocorticoid Use in Pemphigus Vulgaris: Insights from a Retrospective Cohort Study.

    Kaya M, Saraç GA, Acar O, et al.

    Dermatology practical & conceptual 2025; (15(2)) doi:10.5826/dpc.1502a5050.

    PMID: 40401897
  7. 7

    Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.

    Colucci M, Carsetti R, Serafinelli J, et al.

    Frontiers in immunology 2019; (10()):1653 doi:10.3389/fimmu.2019.01653.

    PMID: 31379849
  8. 8

    The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders.

    Gatti A, Buccisano F, Scupoli MT, Brando B

    Cytometry. Part B, Clinical cytometry 2021; (100(2)):194-205 doi:10.1002/cyto.b.21930.

    PMID: 32598578
  9. 9

    Clinical and Immunological Outcomes of Rituximab Therapy in Pemphigus: A Prospective Observational Study.

    Deo KS, Mishra N, Singh Deora M, et al.

    Dermatology (Basel, Switzerland) 2026; (242(2)):145-151 doi:10.1159/000550170.

    PMID: 41442437
  10. 10

    Subtype-specific inherited predisposition to pemphigus in the Chinese population.

    Zhang SY, Zhou XY, Zhou XL, et al.

    The British journal of dermatology 2019; (180(4)):828-835 doi:10.1111/bjd.17191.

    PMID: 30230522
  11. 11

    Psoriasiform Pemphigus Foliaceus in an African American Female: An Important Clinical Manifestation.

    Austin E, Millsop JW, Ely H, et al.

    Journal of drugs in dermatology : JDD 2018; (17(4)):471-473.

    PMID: 29601624
  12. 12

    Pemphigus foliaceus exacerbated by radiation, in association with myasthenia gravis.

    Liebman TN, Lieberman MR, Burris K

    Dermatology online journal 2016; (22(3)).

    PMID: 27136623
  13. 13

    Treatment of Pediatric Pemphigus Foliaceus.

    Carver C, Kalesinskas M, Dheden N, Ahmed AR

    Cureus 2023; (15(9)):e45373 doi:10.7759/cureus.45373.

    PMID: 37779684

This page provides educational information about living with pemphigus foliaceus. It does not replace professional medical advice; always consult your dermatologist or healthcare team regarding your specific monitoring and skincare needs.

Get notified when new evidence is published on Pemphigus foliaceus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.